Triiodothyronine (T3) levels in relation to mortality from breast cancer and all-causes: a population-based prospective cohort study.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Triiodothyronine (T3) levels in relation to mortality from breast cancer and all-causes: a population-based prospective cohort study. / Tosovic, Ada; Bondeson, Anne-Greth; Bondeson, Lennart; Ericsson, Ulla-Britt; Manjer, Jonas.

I: European Journal of Endocrinology, Vol. 168, Nr. 4, 2013, s. 483-490.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - Triiodothyronine (T3) levels in relation to mortality from breast cancer and all-causes: a population-based prospective cohort study.

AU - Tosovic, Ada

AU - Bondeson, Anne-Greth

AU - Bondeson, Lennart

AU - Ericsson, Ulla-Britt

AU - Manjer, Jonas

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200), Surgery Research Unit (013242220), Pathology (Malmö) (013031000)

PY - 2013

Y1 - 2013

N2 - OBJECTIVE: The potential association between thyroid hormones and breast cancer has been investigated in a large number of studies without conclusive results. This study investigated T3 levels in relation to breast cancer mortality in a population with no breast cancer patients at baseline. An additional aim was to study T3 levels in relation to mortality from other cancers and all-cause mortality. DESIGN AND METHODS: This was a population-based prospective cohort study including 2,185 women in whom T3 levels were measured as part of a preventive health project, i.e. before diagnosis in women who later developed breast cancer. Mean follow-up was 24.1 years and record-linkage to The Swedish Cause-of-Death registry identified 471 women who died; 26 out of breast cancer, and 182 from other cancers. Mortality was assessed using a Cox's analysis, yielding hazard ratios (HR), with 95% confidence intervals. Analyses of T3 as a continuous variable were repeated for pre- and peri/postmenopausal women separately. RESULTS: T3 levels were positively associated with the risk of breast cancer specific death in the age-adjusted analysis: HR for T3 as a continuous variable was 2.80 (1.26-6.25). However, the crude analysis did not reach statistical significance. Breast cancer mortality was even higher in postmenopausal women: 3.73 (1.69-8.22), but stratified analyses included few events. There were no statistically significant associations between T3 levels and deaths from other cancers, age-adjusted HR: 1.09 (0.72-1.65) or all-cause mortality (1.25:0.97-1.60). CONCLUSIONS: This study, the first of its kind on prospectively measured T3 levels, indicates that T3 levels are positively associated with breast cancer specific mortality, and that this is not related to a general effect on all-cause mortality.

AB - OBJECTIVE: The potential association between thyroid hormones and breast cancer has been investigated in a large number of studies without conclusive results. This study investigated T3 levels in relation to breast cancer mortality in a population with no breast cancer patients at baseline. An additional aim was to study T3 levels in relation to mortality from other cancers and all-cause mortality. DESIGN AND METHODS: This was a population-based prospective cohort study including 2,185 women in whom T3 levels were measured as part of a preventive health project, i.e. before diagnosis in women who later developed breast cancer. Mean follow-up was 24.1 years and record-linkage to The Swedish Cause-of-Death registry identified 471 women who died; 26 out of breast cancer, and 182 from other cancers. Mortality was assessed using a Cox's analysis, yielding hazard ratios (HR), with 95% confidence intervals. Analyses of T3 as a continuous variable were repeated for pre- and peri/postmenopausal women separately. RESULTS: T3 levels were positively associated with the risk of breast cancer specific death in the age-adjusted analysis: HR for T3 as a continuous variable was 2.80 (1.26-6.25). However, the crude analysis did not reach statistical significance. Breast cancer mortality was even higher in postmenopausal women: 3.73 (1.69-8.22), but stratified analyses included few events. There were no statistically significant associations between T3 levels and deaths from other cancers, age-adjusted HR: 1.09 (0.72-1.65) or all-cause mortality (1.25:0.97-1.60). CONCLUSIONS: This study, the first of its kind on prospectively measured T3 levels, indicates that T3 levels are positively associated with breast cancer specific mortality, and that this is not related to a general effect on all-cause mortality.

U2 - 10.1530/EJE-12-0564

DO - 10.1530/EJE-12-0564

M3 - Article

VL - 168

SP - 483

EP - 490

JO - European Journal of Endocrinology

T2 - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 1479-683X

IS - 4

ER -